In the recent PAR008 release PAR management claimed that there was not just cartilage preservation but growth. This is unheard of in any OA medication study.
So why is there a lack of scientific or media interest?
Why is there a lack of exuberance in the AGM on this point?
Why is there an increase in short interest?
Why would non-executive directors leave?
Why the lack of peer review that has always been promised, for a number of years?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
28.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $115.3M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 28.5¢ | 27.5¢ | $33.59K | 119.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 55300 | 27.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.5¢ | 98947 | 10 |
View Market Depth
| Last trade - 10.15am 18/09/2025 (20 minute delay) ? |
| PAR (ASX) Chart |